Improved immune response against influenza A viruses with receipt of a recombinant influenza vaccine in healthcare personnel with prior low antibody response to egg-based influenza vaccines, Israel, 2019-20.

Abstract

Adult studies have shown that quadrivalent recombinant influenza vaccines (RIV4) induce a higher antibody response than quadrivalent egg-based inactivated influenza vaccines (IIV4). Healthcare personnel (HCP) from a 2018-19 cohort study that assessed IIV4 immunogenicity in Israel were recruited into a 2019-20 randomized trial of RIV4 and IIV4. 2018-19 low titer low responders (LTLRs) had pre-vaccination hemagglutination inhibition antibody titers ≤1:40 and <4-foldrise post-vaccination. We assessed whether RIV4 versus IIV4 receipt in the 2019-20 season improved response among 2018-19 LTLRs using logistic regression adjusted for employment hospital. Of 228 HCP classified as 2018-19 LTLRs, 2019-20 RIV4 recipients were 3.6 (95% CI: 1.2-11.4) and 8.3 (95% CI: 3.0-26.3) times as likely to become a non-LTLR against influenza A(H1N1)pdm09 and cell-derived A(H3N2) vaccine components compared to IIV4 recipients. RIV4 had improved immunogenicity against influenza A viruses among previously classified low vaccine responder HCP, highlighting how recombinant influenza vaccines could improve antibody responses against influenza A for HCP at risk for poor influenza antibody response.